Brain Cancer Clinical Trials in Houston

Showing 101-120 of 170 trials

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

NCT02844439

This is a multicenter, Phase 2 study to assess the activity of tesevatinib in patients with recurrent glioblastoma.

GlioblastomaRecurrent GlioblastomaBrain Tumor

Kadmon Corporation, LLC40 participantsStarted Jun 2016

Tucson, Arizona, United States • Duarte, California, United States • San Francisco, California, United States +8 more locations

COMPLETEDPhase 2< 1 mile

Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer

NCT00871923

The goal of this clinical research study is to learn whether Tarceva (erlotinib hydrochloride), when given in addition to whole brain radiation therapy, is better to treat brain metastases in patients with Non-Small Cell Lung Cancer (NSCLC).

Non-small Cell Lung CancerBrain Cancer

M.D. Anderson Cancer Center44 participantsStarted Mar 2009

Tucson, Arizona, United States • Houston, Texas, United States

COMPLETEDPhase 2< 1 mile

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects

NCT02798406

Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant brain tumor in adults and can be resistant to conventional therapies. The purpose of this Phase II study is to evaluate how well a recurrent glioblastoma or gliosarcoma tumor responds to one injection of DNX-2401, a genetically modified oncolytic adenovirus, when delivered directly into the tumor followed by the administration of intravenous pembrolizumab (an immune checkpoint inhibitor) given every 3 weeks for up to 2 years or until disease progression. Funding Source-FDA OOPD

Brain CancerBrain NeoplasmGlioma+8 more

DNAtrix, Inc.49 participantsStarted Oct 2016

Little Rock, Arkansas, United States • Los Angeles, California, United States • Chicago, Illinois, United States +12 more locations

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects

Brain Cancer Trials in Other Cities

UNITE Study: Understanding New Interventions With GBM ThErapy

Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma

Gliogene: Brain Tumor Linkage Study

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)

Study of Systemic and Spinal Chemotherapy Followed by Radiation for Infants With Brain Tumors

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma

Radiation Therapy in Treating Young Patients With Gliomas

Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme

ANG1005 in Patients With Recurrent High-Grade Glioma

Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas

Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor

Other Conditions in Houston